SCHEMBL4194151

SCHEMBL4194151

Cc1cncc(-c2nc3nccnc3c(=O)n2NCc2ccc(C#N)cc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37
VNN1 O95497 1/20 0.37
CYP11B1 P15538 2/20 0.35
CYP11B2 P19099 2/20 0.35
TRIM24 O15164 3/20 0.35
LOXL2 Q9Y4K0 1/20 0.34
KDM1A O60341 1/20 0.34
HDAC1 Q13547 1/20 0.34
PIK3C2A O00443 2/20 0.34
LRRK2 Q5S007 1/20 0.34
P4HTM Q9NXG6 1/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4194122 0.87 ALDH1A1 (0.35) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL4189608 0.82 KDM4E (0.42) KDM4EALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL4189673 0.77 FYN (0.39) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL4187254 0.64 MAPT (0.44) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL4194113 0.62 DYRK1A (0.46) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL13778328 0.61 NOS1 (0.56) KDM4ECYP11B1CYP11B2LOXL2HDAC1
SCHEMBL4197705 0.59 IDO1 (0.44) KDM4EALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL10175348 0.58 CYP11B2 (0.48) KDM4EALDH1A1CYP11B1CYP11B2MEN1
SCHEMBL10175107 0.58 CYP11B2 (0.47) CYP11B1CYP11B2
SCHEMBL509578 0.57 LOXL2 (1.00) KDM4EALDH1A1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 KDM4E 3848/4885ALDH1A1 2426/4885CYP1A2 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.